I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat 天境生物巨震：管理層變動、收購傳聞、退市風險
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low. 抗癌藥研發公司天境生物最近頻繁出現在一系列影響市場的頭條新聞中，盡管股票仍接近歷史最低點。
There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose stock is getting pulled every which way as a result.
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.